Therefore, there is an urgent need for a better understanding of how individual ligands affect CASR-mediated signaling, and how this will in turn benefit the development of novel pharmaceutical therapies targeting the CASR in CRC. The gene discussed is CASR; the disease is colorectal carcinoma.